| P50 | author | Gregory J Zipfel | Q62069769 |
| | Rawan Tarawneh | Q63978697 |
| | Anne M Fagan | Q66909797 |
| | Gina D'Angelo | Q88608617 |
| | Jack H Ladenson | Q114430750 |
| | David M. Holtzman | Q56827171 |
| | John C. Morris | Q56839763 |
| P2093 | author name string | Dan Crimmins | |
| | Elizabeth Herries | |
| | Terry Griest | |
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| | Harmonized diagnostic criteria for Alzheimer's disease: recommendations | Q27009157 |
| | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| | Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice | Q28511650 |
| | Localization of RC3 (neurogranin) in rat brain subcellular fractions | Q28567404 |
| | Neurogranin targets calmodulin and lowers the threshold for the induction of long-term potentiation | Q28572299 |
| | Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 |
| | Alzheimer's disease is a synaptic failure | Q29547670 |
| | The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 |
| | Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 |
| | Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium | Q29614409 |
| | Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria | Q29614410 |
| | An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest | Q29615076 |
| | The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 |
| | High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation | Q29616564 |
| | A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume | Q30970553 |
| | The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers | Q31081008 |
| | Biomarkers in translational research of Alzheimer's disease | Q33556189 |
| | Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease | Q33591314 |
| | Multimodal techniques for diagnosis and prognosis of Alzheimer's disease | Q33607535 |
| | Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease | Q33731565 |
| | Homeostatic tuning of Ca2+ signal transduction by members of the calpacitin protein family | Q33734794 |
| | Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data | Q34039952 |
| | Subtractive cDNA cloning of RC3, a rodent cortex-enriched mRNA encoding a novel 78 residue protein | Q34153989 |
| | Alzheimer's disease and Abeta toxicity: from top to bottom | Q34325378 |
| | Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop | Q34733901 |
| | Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models | Q35070000 |
| | Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease | Q35158065 |
| | Synaptic slaughter in Alzheimer's disease | Q35595427 |
| | Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies | Q35595432 |
| | Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia | Q35749788 |
| | CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. | Q35835717 |
| | Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease | Q36001286 |
| | Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease | Q36276592 |
| | Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease | Q36412490 |
| | Dendritic spine loss and synaptic alterations in Alzheimer's disease. | Q37148402 |
| | MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers | Q37158181 |
| | [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease | Q60451990 |
| | Postsynaptic injection of Ca2+/CaM induces synaptic potentiation requiring CaMKII and PKC activity | Q71988410 |
| | Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease | Q72119373 |
| | Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI | Q80071452 |
| | Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects | Q81126249 |
| | MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study | Q37178967 |
| | MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change | Q37273569 |
| | Beta-amyloid burden is not associated with rates of brain atrophy | Q37326537 |
| | Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. | Q37366280 |
| | Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type | Q37381205 |
| | Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention | Q37438267 |
| | Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection | Q37639158 |
| | Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity | Q37776215 |
| | Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 |
| | Changes in premorbid brain volume predict Alzheimer's disease pathology | Q40566333 |
| | Synaptic pathology of Alzheimer's disease | Q40779683 |
| | Structural correlates of cognition in dementia: quantification and assessment of synapse change. | Q41443879 |
| | RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes | Q41659791 |
| | Synaptic loss in Alzheimer's disease and other dementias | Q41984306 |
| | ETRAP (efficient trapping and purification) of target protein polyclonal antibodies from GST-protein immune sera. | Q42835499 |
| | Relationship between atrophy and beta-amyloid deposition in Alzheimer disease | Q43107490 |
| | Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components | Q43866611 |
| | Ontogenetic changes in the cyclic adenosine 3',5'-monophosphate-stimulatable phosphorylation of cat visual cortex proteins, particularly of microtubule-associated protein 2 (MAP 2): effects of normal and dark rearing and of the exposure to light | Q44607491 |
| | Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 |
| | Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease | Q45172855 |
| | Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. | Q45942302 |
| | Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease | Q46481511 |
| | Synaptic and neuritic alterations during the progression of Alzheimer's disease | Q46842058 |
| | Neurochemical dissection of synaptic pathology in Alzheimer's disease. | Q47965884 |
| | Imaging beta-amyloid burden in aging and dementia. | Q48168226 |
| | Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 |
| | Synapse loss in the temporal lobe in Alzheimer's disease | Q48338615 |
| | Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients | Q48375577 |
| | Identification of novel brain biomarkers. | Q48466456 |
| | Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype | Q48499517 |
| | Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. | Q48650804 |
| | Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease | Q48790608 |
| | Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction | Q48914501 |
| | Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity | Q48983820 |
| | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. | Q50762201 |
| | Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 |
| | Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 |
| | Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. | Q51996138 |
| | The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. | Q52171007 |
| | Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. | Q52424284 |
| | A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. | Q53193790 |
| | Protection against Alzheimer's disease with apoE epsilon 2. | Q53204350 |
| | Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. | Q53213466 |
| | Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 |
| | Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. | Q53416640 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 561-571 | |
| P577 | publication date | 2016-03-28 | |
| P1433 | published in | JAMA Neurology | Q276813 |
| P1476 | title | Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease | |
| P478 | volume | 73 | |